Understanding GLP-1 and Next-Generation Peptides To understand Retatrutide, it helps to understand GLP-1
Food and Drug Administration (FDA) approval in May 2022 for type 2 diabetes, November 2023 for chronic weight management, and December 2024 for obstructive sleep apnea, marking it as the first approved therapy for this indication
Because systemic inflammation is a driver of almost every chronic disease, reducing it is generally safe and beneficial
From Hollywood red carpets to glossy magazine covers, celebrities are always glowing
Additionally, temperature fluctuations can reduce its effectiveness, making it less effective at controlling blood sugar or aiding in weight loss
Now, theres another potential Ozempic side effect getting attention on social media: Ozempic breasts. Meet the experts: Mir Ali, M.D., bariatric surgeon and medical director of MemorialCare Surgical Weight Loss Center at Orange Coast Medical Center in Fountain Valley, CA